Ander Matheu

Dr. Ander Matheu

Cellular Oncology group, Biodonostia Health Research Institute, E-20014 San Sebastian, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Cancer Research
Verified
Journal Article
Closed access
PDF file
Ander MatheuAnder Matheu
Ander Matheu
Manuel ColladoManuel Collado
Manuel Collado
CWClare Wise
Clare Wise
LMLorea Manterola
Lorea Manterola
LCLina Cekaite
Lina Cekaite
RLRobin Lovell-Badge
Robin Lovell-Badge
SOX9 [sex-determining region Y (SRY)-box 9 protein], a high mobility group box transcription factor, plays critical roles during embryogenesis and its activity is required for development, differentiation, and lineage commitment in various tissues including the intestinal epithelium. Here, we present functional and clinical data of a broadly important role for SOX9 in tumorigenesis. SOX9 was overexpressed in a wide range of human cancers, where its expression correlated with malignant character and progression. Gain of SOX9 copy number is detected in some primary colorectal cancers. SOX9 exhibited several pro-oncogenic properties, including the ability to promote proliferation, inhibit senescence, and collaborate with other oncogenes in neoplastic transformation. In primary mouse embryo fibroblasts and colorectal cancer cells, SOX9 expression facilitated tumor growth and progression whereas its inactivation reduced tumorigenicity. Mechanistically, we have found that Sox9 directly binds and activates the promoter of the polycomb Bmi1, whose upregulation represses the tumor suppressor Ink4a/Arf locus. In agreement with this, human colorectal cancers showed a positive correlation between expression levels of SOX9 and BMI1 and a negative correlation between SOX9 and ARF in clinical samples. Taken together, our findings provide direct mechanistic evidence of the involvement of SOX9 in neoplastic pathobiology, particularly, in colorectal cancer. Cancer Res; 72(5); 1301–15. ©2012 AACR.

7 August 2017 in Aging Cell
Verified
Journal Article
Open access
PDF file
MRMiren Revuelta
Miren Revuelta
Ander MatheuAnder Matheu
Ander Matheu
Summary: Aging is responsible for changes in mammalian tissues that result in an imbalance to tissue homeostasis and a decline in the regeneration capacity of organs due to stem cell exhaustion. Autophagy is a constitutive pathway necessary to degrade damaged organelles and protein aggregates. Autophagy is one of the hallmarks of aging, which involves a decline in the number and functionality of stem cells. Recent studies show that stem cells require autophagy to get rid of cellular waste produced during the quiescent stage. In particular, two independent studies in muscle and hematopoietic stem cells demonstrate the relevance of the autophagy impairment for stem cell exhaustion and aging. In this review, we summarize the main results of these works, which helped to elucidate the impact of autophagy in stem cell activity as well as in age‐associated diseases.

23 February 2016 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Open access
LGLaura Garros-Regulez
Laura Garros-Regulez
PAPaula Aldaz
Paula Aldaz
OAOlatz Arrizabalaga
Olatz Arrizabalaga
VMVeronica Moncho
Veronica Moncho
ECEstefania Carrasco-Garcia
Estefania Carrasco-Garcia
Ander MatheuAnder Matheu
Ander Matheu
Background: SOX2 and SOX9 are commonly overexpressed in glioblastoma, and regulate the activity of glioma stem cells (GSCs). Their specific and overlapping roles in GSCs and glioma treatment remain...

5 July 2019 in Cancers
Verified
Journal Article
Open access
PDF file
ASAnder Saenz-Antoñanzas
Ander Saenz-Antoñanzas
JAJaione Auzmendi
Jaione Auzmendi
ECEstefania Carrasco-Garcia
Estefania Carrasco-Garcia
LMLeire Moreno-Cugnon
Leire Moreno-Cugnon
IRIrune Ruiz
Irune Ruiz
Ander MatheuAnder Matheu
Ander Matheu
Liquid biopsy represents a minimally invasive procedure that can provide similar information from body fluids to what is usually obtained from a tissue biopsy sample. Its implementation in the clinical setting might significantly renew the field of medical oncology, facilitating the introduction of the concepts of precision medicine and patient-tailored therapies. These advances may be useful in the diagnosis of brain tumors that currently require surgery for tissue collection, or to perform genetic tumor profiling for disease classification and guidance of therapy. In this review, we will summarize the most recent advances and putative applications of liquid biopsy in glioblastoma, the most common and malignant adult brain tumor. Moreover, we will discuss the remaining challenges and hurdles in terms of technology and biology for its clinical application.

24 October 2016 in Frontiers in Oncology
Verified
Journal Article
Open access
LGLaura Garros-Regulez
Laura Garros-Regulez
IGIdoia Garcia
Idoia Garcia
ECEstefania Carrasco-Garcia
Estefania Carrasco-Garcia
ALAquilino Lantero
Aquilino Lantero
PAPaula Aldaz
Paula Aldaz
Ander MatheuAnder Matheu
Ander Matheu
Glioblastoma is the most common and malignant brain cancer in adults. Current therapy consisting of surgery followed by radiation and temozolomide therapy has moderate success rate and the tumor reappears. Among the features that a cancer cell must have to survive the therapeutic treatment and reconstitute the tumor is the ability to self-renewal. Therefore, it is vital to identify the molecular mechanisms that regulate this activity. SOX2 is a transcription factor whose activity has been associated with the maintenance of the undifferentiated state of cancer stem cells in several tissues including the brain. Several groups have detected SOX2 levels increased in biopsies of glioblastoma patients, with highest levels associated to poor outcome. Therefore, SOX2 silencing might be a novel therapeutic approach to combat cancer and particularly brain tumors.In this review, we will summarize the current knowledge about SOX2 in glioblastoma and recapitulate several strategies, which have been recently described targeting SOX2 in this malignancy.

14 November 2016 in Cancer Research
Verified
Journal Article
Open access
PDF file
JSJuliana Santos
Juliana Santos
ECEstefania Carrasco-Garcia
Estefania Carrasco-Garcia
MGMikel García-Puga
Mikel García-Puga
PAPaula Aldaz
Paula Aldaz
MMMilagrosa Montes
Milagrosa Montes
Ander MatheuAnder Matheu
Ander Matheu
Gastric cancer remains one of the leading causes of global cancer mortality due to therapy resistance, with Helicobacter pylori (H. pylori) infection being a major risk factor. In this study, we report the significance of an elevation of the stem cell regulator SOX9 in bacteria-infected human gastritis and cancer samples, paralleling increased levels of TNFα. SOX9 elevation was more intense in specimens containing the pathogenically significant cagA+ strains of H. pylori. Notably, we found that SOX9 was required for bacteria-induced gastric cancer cell proliferation, increased levels of β-catenin, and acquisition of stem cell–like properties. Analysis of three large clinical cohorts revealed elevated SOX9 levels in gastric cancer with advanced tumor stage and poor patient survival. Functionally, SOX9 silencing in gastric cancer cells enhanced apoptosis and senescence, concomitantly with a blockade to self-renewal and tumor-initiating capability. Paralleling these effects, we also found SOX9 to mediate cisplatin chemoresistance associated with reduced disease-free survival. Mechanistic interactions between SOX9 and β-catenin expression suggested the existence of a regulatory role for SOX9 targeting the WNT canonical pathway. Taken together, our findings establish the significance of SOX9 in gastric cancer pathobiology and heterogeneity, with implications for targeting WNT–SOX9 signaling as a rational therapeutic strategy. Cancer Res; 76(22); 6735–46. ©2016 AACR.